Get the Stockscreener App
1.04
5.05%
0.05
After Hours:
1.06
0.02
+1.92%
Celularity Inc stock is traded at $1.04, with a volume of 33,508.
It is up +5.05% in the last 24 hours and down -14.75% over the past month.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
See More
Previous Close:
$0.99
Open:
$1
24h Volume:
33,508
Relative Volume:
0.23
Market Cap:
$29.99M
Revenue:
$40.58M
Net Income/Loss:
$-80.65M
P/E Ratio:
-0.3122
EPS:
-3.331
Net Cash Flow:
$-8.11M
1W Performance:
-14.75%
1M Performance:
-14.75%
6M Performance:
-48.00%
1Y Performance:
-33.50%
1-Day Range:
$1.00
$1.04
1-Week Range:
$0.9633
$1.25
52-Week Range:
$0.9633
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
1.04 | 28.55M | 40.58M | -80.65M | -8.11M | -3.331 |
VRTX
Vertex Pharmaceuticals Inc
|
430.14 | 108.36B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
731.77 | 78.05B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
775.03 | 48.74B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.11 | 41.16B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
298.16 | 33.17B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
NEXGEL Closes Celularity Asset Deal, Launches BioNX Surgical - MyChesCo
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Investing News Network
NEXGEL taps M&A veteran as CFO to steer Celularity integration - Stock Titan
NEXGEL expects pro forma annual revenue of roughly $35M following Celularity wound segment acquisition - MSN
Inside the deal: After investor bails, Nexgel scrambles to save acquisition that will triple revenue - The Business Journals
Celularity receives Nasdaq notification - MSN
Celularity Inc (CELU) insider Form 3 details warrants and convertible notes - Stock Titan
Celularity Inc (CELU) insider lists warrant and note holdings - Stock Titan
Barach Family Trust (CELU) reports warrants and convertible notes in Celularity Form 3 - Stock Titan
CELU Celularity tops Q3 2025 EPS estimates and posts sharp revenue growth, as shares dip 2.08%.Guidance Upgrade - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELU) What Lies Ahead | Celularity Inc posts 42.5% EPS beat, narrower lossDistressed Pick - Cổng thông tin điện tử tỉnh Lào Cai
Celularity (CELUW) Stock: Is It Breaking Uptrend Earnings ReportNCAV - Xã Thanh Hà
CELU (Celularity Inc.) Q3 2025 EPS beats analyst expectations, registers a small post-earnings stock dip.Community Exit Signals - Cổng thông tin điện tử tỉnh Lào Cai
Family trust reports 20.1% Celularity (CELU) stake from $10M financing - Stock Titan
NEXGEL Reschedules Shareholder Call, Revises Celularity Financing - MyChesCo
NEXGEL closes Celularity biomaterials deal, raises $5.5 million By Investing.com - Investing.com India
Celularity Announces Closing of Transaction with NexGel - Investing News Network
Nexgel Inc co and Celularity enter amendment no. 1 to license agreement on April 17, 2026 - marketscreener.com
Nexgel IncCo to Pay Celularity $13.3 Mln I - Moomoo
NEXGEL (NASDAQ: NXGL) triples revenue outlook with Celularity deal, $6.9M notes - Stock Titan
Celularity Inc. announced that it has received $13.3 million in funding from NEXGEL, Inc. - marketscreener.com
NexGel closes acquisition of products from Celularity - TipRanks
Celularity Closes $13.3 Million Asset Sale to NexGel, Strengthening Focus on Longevity Therapeutics and Balance Sheet 1 - Minichart
NEXGEL New Strategic Partner, Sequence LifeScience, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Investing News Network
Nexgel new strategic partner, Sequence LifeScience, leads financing with $5.5 million to complete acquisition of Celularity degenerative disease segment - marketscreener.com
Celularity Closes NexGel Asset Sale, Refocuses on Cell Therapy - TipRanks
NEXGEL closes Celularity biomaterials deal, raises $5.5 million - Investing.com
Biomaterials company Nexgel announces a key partnership with new strategic partner Sequence Lifescience™ - Bitget
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - The Manila Times
Celularity Inc. Announces Management Resignations - marketscreener.com
Celularity (NASDAQ: CELU) closes NexGel asset sale as Helena note default looms - Stock Titan
A $5.5M financing gives NEXGEL 6 regenerative products and a new unit - Stock Titan
Celularity Closes Transaction with NexGel to Monetize Biomaterials - Intellectia AI
NEXGEL, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
NEXGEL, Inc. completed the acquisition of Portfolio of Commercial-stage Regenerative Biomaterial Products of Celularity Inc. for 15.8 million. - marketscreener.com
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing - The Manila Times
Celularity receives Nasdaq notice for delayed annual report filing By Investing.com - Investing.com Australia
Celularity receives Nasdaq notice for delayed annual report filing - Investing.com
CELULARITY ANNOUNCES RECEIPT OF NASDAQ NOTICE REGARDING LATE FORM 10-K FILING - Moomoo
Celularity announces receipt of Nasdaq notice regarding late form 10-K filing - marketscreener.com
Celularity Inc. Notifies Nasdaq of Non-Compliance with Listing Rules Due to Delay in Annual Report Filing - Quiver Quantitative
NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET - The Manila Times
RSU vesting lifts Celularity (CELU) insider holdings after tax withholding - Stock Titan
Celularity (NASDAQ: CELU) EVP RSUs vest into shares with tax withholding - Stock Titan
Celularity (NASDAQ: CELU) CEO gains shares from RSU vesting - Stock Titan
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - The Manila Times
NEXGEL Reschedules Shareholder Update Conference Call to - GlobeNewswire
Aug Gainers: What is Celularity Inc Equity Warrants market position2026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Trend Recap: Is Celularity Inc stock risky to hold now2026 Summary & Verified Technical Trade Signals - baoquankhu1.vn
Risk Recap: Is Celularity Inc Equity Warrant a strong candidate for buy and hold2026 Stock Rankings & Momentum Based Trading Signals - baoquankhu1.vn
NEXGEL signs agreement to acquire regenerative biomaterial portfolio - MSN
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Celularity Inc Stock (CELU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
0.29%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):